MTOR and colorectal carcinoma: We also tested the combinational effect of tankyrase/mTOR inhibition in two additional CRC cell lines, HCC2998 and DLD-1, which have KRAS mutations and more common APC mutations with two 20-AAR (20-amino acid repeat) motifs.